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Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular dysplastic
disorder, characterized by recurrent nosebleeds (epistaxis), multiple telangiectases and
arteriovenous malformations (AVMs) in major organs. Mutations in Endoglin (ENG or
CD105 ) andActivin receptor-like kinase 1 (ACVRL1 orALK1) genes of theTGF-β superfamily
receptors are responsible for HHT1 and HHT2 respectively and account for the majority of
HHT cases. Haploinsufﬁciency in ENG and ALK1 is recognized at the underlying cause
of HHT. However, the mechanisms responsible for the predisposition to and generation
of AVMs, the hallmark of this disease, are poorly understood. Recent data suggest that
dysregulated angiogenesis contributes to the pathogenesis of HHT and that the vascular
endothelial growth factor, VEGF, may be implicated in this disease, by modulating the
angiogenic–angiostatic balance in the affected tissues. Hence, anti-angiogenic therapies
that target the abnormal vessels and restore the angiogenic–angiostatic balance are can-
didates for treatment of HHT. Here we review the experimental evidence for dysregulated
angiogenesis in HHT, the anti-angiogenic therapeutic strategies used in animal models and
some patients with HHT and the potential beneﬁt of the anti-angiogenic treatment for
ameliorating this severe, progressive vascular disease.
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HHT IS A SEVERE SYSTEMIC VASCULAR DYSPLASTIC
DISEASE
Hereditary hemorrhagic telangiectasia (HHT) is an inherited
systemic vascular dysplastic disorder, associated with multiple
mucocutaneous telangiectases, recurrent nasal and gastrointesti-
nal bleeding episodes and large arteriovenous malformations
(AVMs) in lungs, liver and brain. More than 80% of HHT patients
carry a mutation in Endoglin (ENG; HHT1) or Activin receptor-
like kinase 1 (ACVRL1; HHT2) genes that code for receptors of
the transforming growth factor β (TGF-β) superfamily. Reduced
expression of ENG and ACVRL1 (haploinsufﬁciency) leads to a
similar HHT phenotype. However, there is a higher incidence of
pulmonary and cerebral AVMs in HHT1, while hepatic AVMs and
gastrointestinal telangiectases are more often diagnosed in HHT2
patients (Friesel et al., 1987; Govani and Shovlin, 2009; Storch and
Hoeger, 2010). This suggests that the HHT phenotype is inﬂu-
enced by the tissue distribution and functionof ENG andACVRL1.
Although pulmonary arterial hypertension (PAH) is a much rarer
event than the occurrence of HHT, it has also been associated
withACVRL1 and ENG mutations (Govani and Shovlin, 2009). In
these cases, PAH likely results from a dysfunctional relationship
betweenACVRL1, ENG and the bonemorphogenic protein recep-
tor type II, BMPR2, another member of the TGF-β superfamily of
receptors, whose mutations are often the cause of inherited as well
as sporadic cases of PAH (Atkinson et al., 2002). Despite exten-
sive work in HHT, no cure for this disease exists. Symptomatic
treatments, including AVM embolization, offer some relief, yet
HHT is a progressive, severe and potentially life-threatening dis-
ease. Recent experimental data and some clinical studies suggest
that anti-angiogenic therapies targeting the abnormal vasculature
may have some beneﬁts in HHT.
DYSREGULATED ANGIOGENESIS IN HHT
In HHT, the mechanisms leading to predisposition and forma-
tion of AVMs, the direct connections between arteries and veins,
are yet to be determined. One proposed mechanism is defec-
tive arteriovenous differentiation, observed in Eng and Alk1 null
embryos that developAVMs (Oh et al., 2000; Sorensen et al., 2003),
but absent in the endothelial-targeted Eng (Eng-iKOe) and Alk1
inducible knockout (Alk1-iKOe) mice (Tual-Chalot et al., 2014).
Moreover, focal regression of capillaries leading to formation of
AVMs has also been postulated in HHT, however, supporting
data for this model are still lacking (Lopez-Novoa and Bernabeu,
2010). Recently, it was shown that wound injury was necessary for
development of AVMs in adult Alk1-iKOe (Park et al., 2009) and
Eng1-iKOe mice (Garrido-Martin et al., 2014). In addition, intrac-
erebral injection of an adenovirus expressing VEGF contributed
to pathogenesis of cerebral AVMs in several transgenic Eng KO
mice (Choi et al., 2014). Interestingly, AVMs were found more
often at the site of vascular injury or turbulent ﬂow, indicating
that these local vascular changes may precipitate the development
of AVMs.
We demonstrated that dysregulated angiogenesis occurs in
Eng+/− and Alk1+/− mouse models of HHT. Angiogenesis is the
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de novo formation of vessels from the pre-existent vascular tree, in
response to a stimulus. This biological process is controlled by pro-
angiogenic factors that promote vascular growth and angiostatic
factors that induce vascular regression. Physiological angiogen-
esis occurs during development and in healthy individuals, in
wound injury and repair, menstruation, pregnancy (Reisinger
et al., 2007), and in testis (Collin and Bergh, 1996) and hair folli-
cles (Yano et al., 2003). Under normal conditions, angiogenesis is
short-lived, due to ﬁnely tuned regulatory mechanisms. In con-
trast, pathological angiogenesis is abnormal, persists indeﬁnitely
and leads to excessive or insufﬁcient generation of new vessels and
likely to abnormal ones such as AVMs (Figure 1). Pathological
angiogenesis contributes to disease progression in cancer (Nagy
et al., 2010), chronic inﬂammatory and chronic infectious dis-
eases (Carmeliet, 2003). However, the possibility that pathological
angiogenesis occurs in HHT has not been explored previously. A
few clinical studies showed that vascular endothelial growth fac-
tor VEGF, a major angiogenic protein, was elevated in circulation
and tissues in HHT patients (Sadick et al., 2005a,b). In addition, it
was reported that Alk1+/− mice had higher VEGF mRNA and
protein levels in lungs, liver and intestine, when compared to
wild type (WT) mice (Shao et al., 2009). These data suggested
that VEGF might play a pathogenic role in HHT and that tar-
geting VEGF in animal models of HHT and patients could be
beneﬁcial.
Pathological angiogenesis can be evaluated in experimental
models by several approaches, frommeasuring the levels of angio-
static and angiogenic factors in tissues and circulation to in vitro
and in vivo quantiﬁcation of tissue microvessel density (MVD).
To investigate if pathological angiogenesis occurs in HHT,we used
the adult Eng+/− andAlk1+/− mice on the C57BL/6 background.
Eng+/− and Alk1+/− mice lack AVMs, but develop pulmonary
peripheral vascular rarefaction, associated with right ventricular
FIGURE 1 | Dysregulated angiogenesis in HHT. Normally, when
quiescent vessels are activated, they proliferate, migrate and mature until
the physiological needs of the organ have been met, and then regress.
Pathological angiogenesis commences when the angiogenic–angiostatic
balance is disrupted, leading to dysregulated angiogenesis, excessive or
reduced tissue MVD and possibly to AVMs. In Eng+/− and Alk1+/−
models of HHT, an imbalance in the pulmonary angiostatic TSP-1 and
vascular destabilizing factor Ang-2 respectively, led to reduced peripheral
lung MVD in both models. However, it is unknown if dysregulated
angiogenesis is involved in the development of AVMs in HHT.  Angiogenic
factors; angiostatic proteins.
hypertrophy (RVH) and spontaneous PAH (Toporsian et al., 2010;
Jerkic et al., 2011). Recently, we demonstrated that the lungs are
the only organ showing pathological angiogenesis or reduced
MVD in both Eng+/− and Alk1+/− mice (Ardelean et al., 2014a).
The reduction in peripheral lung MVD was associated with a
genotype-speciﬁc molecular angiogenic–angiostatic imbalance.
Eng+/− lungs had a fourfold increase in the angiostatic fac-
tor thrombospondin-1 (TSP-1), which was inversely correlated
with the endoglin levels. This ﬁnding was conﬁrmed in vitro in
endoglin-deﬁcient endothelial cells. In contrast, Alk1+/− lungs
showed an augmentation in the vascular destabilizing proteinAng-
2, whereas the tissue TSP-1 was normal. However, in both Eng+/−
and Alk1+/− lungs, the levels of the major pro-angiogenic and
vascular regulator VEGF were unchanged when compared to WT
mice, suggesting that factors other than VEGF are implicated in
modulation of the tissue angiogenic–angiostatic balance in these
mouse models of HHT. These data indicate that an impairment
in the molecular balance of angiogenic and angiostatic factors
can lead to changes in tissue MVD, in disorders of dysregulated
angiogenesis, such as HHT (Figure 1).
Furthermore, a 70% increase in TSP-1 levels was also noted in
the liver of Eng+/− mice versusWT littermates, whereas theVEGF
levels were normal. This hepatic imbalance in the TSP-1/VEGF
levels was not accompanied by an alteration in liver MVD in
Eng+/− mice, indicating that a critical molecular threshold must
be reached in the levels of angiostatic versus pro-angiogenic fac-
tors in order to affect tissue MVD. The liver of Alk1+/− mice had
normal MVD and tissue levels of Ang-2 and VEGF.
Surprisingly, even though VEGF does not appear to play a
major pathogenic role in Eng+/− and Alk1+/− mice, blocking
VEGF with the monoclonal antibody G6-31 led to improvement
in the molecular and microvascular phenotype in the affected
lungs of these mice (Ardelean et al., 2014a). Anti-VEGF treatment
normalized the pulmonary TSP-1 and Ang-2 levels in Eng+/−
and Alk1+/− mice respectively, increased and restored the lung
peripheral MVD and alleviated the RVH in the treated mice.
This suggests that VEGF may be a critical regulator of multi-
ple angiogenic pathways in HHT. Thus, we speculate that the
anti-VEGF treatment, by decreasing the pulmonary VEGF lev-
els in both Eng+/− and Alk1+/− mice, reduced the tissue TSP-1
and Ang-2 levels respectively, either (a) directly or (b) possibly
via p38 MAPK, a protein involved in signaling transduction for
VEGF, some of the TGF-β superfamily of ligands, TSP-1 and
Ang-2. However, these currently unknown mechanisms need to
be investigated.
In support of the concept that VEGF is a critical angiogenic
regulator, G6-31 treatment also led to prevention and reversal of
mucocutaneous AVMs in Alk1-iKOe mouse model of HHT (Han
et al., 2014), indicating that a reduction in VEGF levels is able to
inhibit the growth of AVMs. Thus, anti-VEGF treatment restored
the tissueTSP-1 levels and improved the pulmonarymicrovascular
phenotype in Eng+/− and Alk1+/− mice, while it prevented and
halted the generation of AVMs in the Alk1 iKOe model of HHT.
ANTI-ANGIOGENIC THERAPEUTIC STRATEGIES IN HHT
Judath Folkman, the pioneer of angiogenesis and anti-angiogenic
therapy, proposed that angiogenesis can be blocked directly, using
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drugs that alter EC migration and proliferation or indirectly, via
modulation of growth factors that act on the vascular endothe-
lium (Folkman and Klagsbrun, 1987). As HHT is a systemic
vascular dysplasia of dysregulated angiogenesis, medication that
targets directly or indirectly the abnormal vessels could have ben-
eﬁcial effects in this disease. For example, anti-VEGF treatment
and thalidomide that have been tested in HHT exert direct anti-
angiogenic properties. Propranolol and timolol are in the process
of being tested in HHT and have mostly indirect anti-angiogenic
effects. Tacrolimus, interferon (IFN)-α and inﬂiximab, used only
in isolated cases of HHT, are predominantly immunomodu-
latory drugs with some anti-angiogenic capabilities (Table 1).
Here, the role of immune system in pathogenesis of HHT is
mostly unknown.Whether dysfunctional immune cells contribute
directly or indirectly to pathological angiogenesis and whether
immunomodulatory therapies could be beneﬁcial in patients
diagnosed with HHT, need to be determined.
ANTI-VEGF TREATMENT
Recently we have shown that G6-31, a monoclonal antibody that
blocksVEGF,had unexpected pro-angiogenic effects, reversing the
rareﬁed peripheral lung microvasculature and restoring the tissue
TSP-1 and Ang-2 levels in Eng+/− and Alk1+/− mouse models of
HHT, respectively (Ardelean et al., 2014a; Table 1).
Table 1 | Mechanisms of several anti-angiogenic and immunomodulatory therapies in HHT.
Therapy Angiogenic
effects
Evidence Immuno-
modulator
Evidence
Tested in patients with HHT
Anti-VEGF
(G6-31 murine
monoclonal
antibody)
+++ ↑ MVD, ↓TSP-1, and ↓ Ang-2 in lungs of Eng+/−and
Alk1+/− mice, respectively (Ardelean et al., 2014a)
↓ vessel area and density in the skin of Alk1 iKO
mouse (Han et al., 2014)
+ ↓ inﬂammation in the colon of DSS-induced
Eng+/− colitis (Ardelean et al., 2014b) and the
skin of JunB and c-Jun iKO mice (Schonthaler
et al., 2009)
Thalidomide ++ High dose (200 mg/kg)
↓ vascular area in rabbit cornea (D’Amato et al., 1994)
↓ VEGF, migration and tube formation in EA.hy 926 EC
(Komorowski et al., 2006)
↓ VEGFR2 and neuropilin-1 in zebraﬁsh embryos
(Yabu et al., 2005)
Low dose (75 mg/kg)
↑ pericyte recruitment in neonatal mouse retina
(Lebrin et al., 2010)
++ ↓ human monocyte-dependent secretion of
several cytokines
↑ proliferation and function of circulating
humanT lymphocytes
↓ number of adhesion molecules in HUVEC
↑ number of NK cells in human multiple
myeloma cell lines (Teo, 2005)
To be tested in HHT patients
Propranolol ++ ↓ proliferation and ↑ apoptosis in HUVEC (Xie et al.,
2013)
↓ VEGF and MMP-9 in hemangioma-derived EC
(Storch and Hoeger, 2010)
↓ endoglin, ACVRL1, PAI-1 in HMEC-1 and HUVEC
(Albinana et al., 2012)
+ ↑ number of T cells,
↓ NK cell activity in human blood (Maisel et al.,
1991)
Not yet proposed for HHT patients
Tacrolimus + ↓ VEGF-induced mouse EC tube formation
(Siamakpour-Reihani et al., 2011)
↑ endoglin and Alk1 in HUVEC
(Albinana et al., 2011)
+++ ↓T-cell activation in mouse spleen andT cell
hybridoma, and in PBMC (Kino et al., 1987;
Bierer et al., 1991)
IFN-α + ↓ EC migration and proliferation in HUVEC
(Friesel et al., 1987)
+++ Anti-viral in human blood (Neumann et al.,
1998), immunomodulation in human blood
(Blanco et al., 2001)
Inﬂiximab + ↓ MVD, VEGF, and EC migration in human intestinal
tissue and EC (Rutella et al., 2011)
+++ Binds soluble and membraneTNF-α in mouse
myeloma cells (Scallon et al., 2002)
DSS, dextran sodium sulfate; HMEC-1, human microvascular endothelial cells; iKO, conditional inducible knockout; MMP-9, matrix metallopeptidase; NK, natural killer
cells; PBMC, peripheral blood mononuclear cell; VEGFR2, vascular endothelial growth factor receptor 2.
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Several clinical reports noted thatHHTpatients treated system-
ically with 5-10 mg/kg of bevacizumab, a humanized anti-VEGF
antibody, showed a signiﬁcant improvement in the frequency
of epistaxis, number of required blood transfusions and that
some patients no longer needed a liver transplantation (Mitchell
et al., 2008; Bose et al., 2009; Oosting et al., 2009; Retornaz et al.,
2009). These data were conﬁrmed in a phase 2 clinical trial that
included HHT patients with severe liver involvement (Dupuis-
Girod et al., 2012). Interestingly, ﬁve of the eight patients treated
in this trial with the anti-VEGF therapy also showed alleviation
of secondary PAH. However, the effects of anti-VEGF therapy
on lung and brain AVMs have not been studied to date in HHT
patients.
Other studies demonstrated that intranasal topical or submu-
cosal injections of bevacizumab, at 25–100 mg/dose, decreased
the frequency of epistaxis in several HHT patients (Simonds et al.,
2009; Chen et al., 2011). Yet, the mechanisms through which
bevacizumab exerted these effects are poorly understood.
Despite these promising results, anti-VEGF treatment, espe-
cially at highdose and/or administered for long-term, canhave side
effects including hypertension, severe proteinuria, gastrointesti-
nal bleeding, and wound dehiscence (Pavlidis and Pavlidis, 2013).
These effects are reversible and possibly avoided with close mon-
itoring, lower doses and shorter regimens of anti-VEGF therapy.
For example, systemic bevacizumab at 1 mg/kg showed promis-
ing results by reducing nasal and gastrointestinal bleeding in a
patient with HHT (Suppressa et al., 2011). Moreover, preliminary
results of a phase-1 double-blind single center study, evaluating
the safety of a bevacizumab nasal spray in HHT-associated epis-
taxis, suggested no outcome differences between low (12.5 mg),
intermediate (50 and 75 mg), or high (100 mg) doses (Dupuis-
Girod et al., 2014). Therefore, lower intranasal anti-VEGF doses
may be the preferred therapeutic approach in reducing the nose-
bleeds inHHT.Overall, off-label use of anti-VEGF therapy showed
promising results in HHT. However, caution is warranted, as the
mechanisms of AVM formation in HHT are yet to be determined
and the effects of this therapy, particularly on lung and brain
AVMs, are still unknown.
THALIDOMIDE
Thalidomide and the second-generation analog lenalidomide, are
medications with anti-angiogenic and immunomodulatory effects
(Table 1), used clinically in multiple myeloma and erythema
nodosum of leprosy (Teo, 2005). The anti-angiogenic effects of
thalidomide are dose-dependent (Table 1).
In HHT patients, thalidomide given orally at 50–200 mg/day
decreased the number of telangiectases, epistaxis and transfusions
(Chen et al., 2012; Franchini et al., 2013). However, thalidomide
doses ≥100 mg per day can cause peripheral neuropathy, somno-
lence, constipation and deep vein thrombosis. The side effects of
thalidomide can be attenuated by reducing the dose given (Teo,
2005).
In several HHT patients, oral lenalidomide at 10–15 mg/day,
reduced the number of gastrointestinal bleeds (Bowcock and
Patrick, 2009). Lenalidomide inhibited VEGF production and
migration of EC, hence showed anti-angiogenic properties, and
had improved immunomodulatory effects and safety proﬁle, when
compared to thalidomide. The most common side effects of
lenalidomide were anemia, constipation and drowsiness (Teo,
2005).
PROPRANOLOL AND TIMOLOL
Propranolol and timolol are non-selective beta-adrenergic recep-
tor (β-AR) blockers with anti-angiogenic properties (Table 1).
Both medications are vasoconstrictive by inhibiting the effects of
adrenaline on the endothelial β-AR. Propranolol showed anti-
proliferative and apoptotic effects on human umbilical vein
endothelial cells (HUVEC; Xie et al., 2013), hence, has anti-
angiogenic properties (Table 1). In addition, propranolol reduced
VEGF and MMP-9 tissue expression (Storch and Hoeger, 2010),
thus indirectly inhibiting angiogenesis. Interestingly, propranolol
diminished in vitro endoglin and ACVRL1 mRNA and protein
levels. It also decreased PAI-1 levels, a downstream protein of
the TGF-β1-ALK5-endoglin-mediated signaling pathway, effect
that can increase bleeding in HHT (Albinana et al., 2012). Clini-
cal data to conﬁrm these potentially undesirable effects in HHT
are lacking. One case report indicated that intranasal timolol
(0.5% ophthalmic solution) reduced the frequency and sever-
ity of epistaxis in one HHT patient, after 3–4 days of treatment
(Olitsky, 2012). The results of a clinical trial testing the effect of
topical timolol on cutaneous telangiectases in HHT are pending
(http://clinicaltrials.gov/show/NCT01752049).
TACROLIMUS (FK506, PROGRAF)
Tacrolimus is an immunomodulator macrolide with anti-
angiogenic properties (Table 1), used in organ transplantation
(Posadas Salas and Srinivas, 2014), some patients with rheuma-
toid arthritis, lupusnephritis (Tanaka et al., 2012), ulcerative colitis
(Inoue et al., 2013) and topically, in severe eczema and vitiligo.
One case report noted that a woman diagnosed with HHT,
hepatic AVMs and high-output cardiac failure, treated in the
ﬁrst year post liver transplantation with sirolimus (rapamycin),
an inhibitor of mTOR, low dose tacrolimus (trough levels 2–
5 ng/ml/day), prednisone (5 mg/day in the ﬁrst 6 months) and
aspirin (81 mg/day), experienced cessation of mucosal bleeding,
normalization of hemoglobin levels and disappearance of cuta-
neous and gastrointestinal telangiectases. This suggests that the
combined immunosuppressive therapy might have exerted anti-
angiogenic effects on telangiectases (Skaro et al., 2006). Patients
treated with tacrolimus need to bemonitored for potential adverse
effects, such as severe infections, hypertension, renal and central
nervous system dysfunction.
INTERFERON-α
Interferon-α is a cytokine with anti-viral and immunoregulatory
properties, used to treat some patients with chronic hepatitis and
certain hematological cancers (Platanias, 2005). IFN-α binds to
type I IFN receptors, inducing their phosphorylation, stimulation
of the transcription factors Stat1 and Stat2, and activation of mul-
tiple target genes. However, it is less known that IFN-α also has
some anti-angiogenic properties (Friesel et al., 1987; Table 1).
In two patients with HHT and co-morbidities, metastatic renal
cancer and chronic hepatitis C respectively, INF-α (3 million units
injected subcutaneously three times a week for 3 and 30 months
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respectively) had beneﬁcial effects on epistaxis and telangiectases
(Massoud et al., 2004; Wheatley-Price et al., 2005). Potential side
effects of IFN-α include decrease in blood cell count, and liver and
thyroid dysfunction.
INFLIXIMAB (REMICADE)
Inﬂiximab is a chimeric anti-tumor necrosis factor (TNF)-αmon-
oclonal antibody that binds soluble andmembrane-boundTNF-α.
Thus, it is used to treat rheumatic and inﬂammatory bowel dis-
eases (IBD; Willrich et al., 2014). Recent in vivo and in vitro data
from patients diagnosed with IBD and treated with inﬂiximab
indicated that this anti-TNF-α antibody had some anti-angiogenic
properties (Rutella et al., 2011; Table 1).
Interestingly, inﬂiximab (5 mg/kg intravenously administered
every 8 weeks for a total of 40 infusions) given to a 21 year-old
man with refractory Crohn’s disease and HHT, on chronic iron
infusions, reduced the frequency of nosebleeds and stabilized the
hemoglobin levels after the third dose (Papa et al., 2010). As HHT
is a non-inﬂammatory vasculopathy, this observation supports
the concept that inﬂiximab might have intrinsic anti-angiogenic
properties that could be beneﬁcial in HHT. Given that inﬂiximab
is an immunomodulatory medication, several adverse effects can
occur: severe infections, demyelinating diseases and potentially
lymphomas (Willrich et al., 2014).
CONCLUSION
Dysregulated angiogenesis, inducedby a tissue imbalance in angio-
genic and angiostatic factors, plays a role in the pathogenesis
of HHT. However, the mechanisms that predispose to and are
responsible for AVM formation in HHT are yet to be discovered.
Surprisingly, VEGF blockage led to increased MVD and restora-
tion of the TSP-1 and Ang-2 balance in the lungs of Eng+/−
and Alk1+/− mice respectively, and prevented or decreased AVM
formation in the Alk1 iKOe mice. Hence, even though VEGF is
not a major pathogenic factor, it acts as a critical modulator of
angiogenesis in HHT.
Drugs that target directly or indirectly the angiogenic vessels
and the master angiogenic regulator VEGF, showed promising
results in HHT. However, caution is warranted, as systemic
anti-angiogenic treatment can also alter the vasculature in the
unaffected organs. The potential side effects of systemic anti-
angiogenic therapy are generally reversible with discontinuation
of treatment. Moreover, the effects of anti-VEGF therapy on
human AVMs are currently unknown. Several immunomodula-
tory agents display some anti-angiogenic properties. In addition,
immune modulation, possibly through regulation of common
immune and angiogenic pathways, may be an option for patients
with HHT and co-morbidities of immune dysregulation. Over-
all, anti-angiogenic therapies showed some encouraging results
in HHT. However, more mechanistic studies and larger clinical
trials are required to fully understand the implications of using
anti-angiogenic therapies in HHT.
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